This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Armeanu, S. Articles by Salih, H. R. Search for Related Content PubMed PubMed Citation Articles by Armeanu, S. Articles by Salih, H. R.

Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma

Authors' Affiliations: Departments of ¹ Gastroenterology and Hepatology; and ² Department of Hematology and Oncology, Medical University Hospital; ³ Department of Immunology, Medical University Hospital, Tübingen, Germany; ⁴ Center for Liver Cell Research, University Hospital, Regensburg, Germany

Requests for reprints: Michael Bitzer or Helmut Salih, University Hospital, Otfried Mueller-Str. 10, D-72076 Tübingen, Germany. Phone: 49-7071-2982712; Fax: 49-707129-4402; E-mail: michael.bitzer{at}uni-tuebingen.de or helmut.salih{at}med.uni-tuebingen.de.

Purpose: Hepatocellular carcinoma (HCC) displays particular resistance to conventional cytostatic agents. Alternative treatment strategies focus on novel substances exhibiting antineoplastic and/or immunomodulatory activity enhancing for example natural killer (NK) cell antitumor reactivity. However, tumor-associated ligands engaging activating NK cell receptors are largely unknown. Exceptions are NKG2D ligands (NKG2DL) of the MHC class I-related chain and UL16-binding protein families, which potently stimulate NK cell responses. We studied the consequences of proteasome inhibition with regard to direct and NK cell–mediated effects against HCC.

Experimental Design: Primary human hepatocytes (PHH) from different donors, hepatoma cell lines, and NK cells were exposed to Bortezomib. Growth and viability of the different cells, and immunomodulatory effects including alterations of NKG2DL expression on hepatoma cells, specific induction of NK cell cytotoxicity and IFN- production were investigated.

Results: Bortezomib treatment inhibited hepatoma cell growth with IC₅₀ values between 2.4 and 7.7 nmol/L. These low doses increased MICA/B mRNA levels, resulting in an increase of total and cell surface protein expression in hepatoma cells, thus stimulating cytotoxicity and IFN- production of cocultured NK cells. Importantly, although NK cell IFN- production was concentration-dependently reduced, low-dose Bortezomib neither induced NKG2DL expression or cell death in PHH nor altered NK cell cytotoxicity.

Conclusions: Low-dose Bortezomib mediates a specific dual antitumor effect in HCC by inhibiting tumor cell proliferation and priming hepatoma cells for NK cell antitumor reactivity. Our data suggest that patients with HCC may benefit from Bortezomib treatment combined with immunotherapeutic approaches such as adoptive NK cell transfer taking advantage of enhanced NKG2D-mediated antitumor immunity.

This article has been cited by other articles:

				H. R. Salih and A. Steinle Reinforcing natural killers Blood, June 11, 2009; 113(24): 6042 - 6043. [Full Text] [PDF]

				J. E. Butler, M. B. Moore, S. R. Presnell, H.-W. Chan, N. J. Chalupny, and C. T. Lutz Proteasome Regulation of ULBP1 Transcription J. Immunol., May 15, 2009; 182(10): 6600 - 6609. [Abstract] [Full Text] [PDF]

				A. Cerwenka New twist on the regulation of NKG2D ligand expression J. Exp. Med., February 16, 2009; 206(2): 265 - 268. [Abstract] [Full Text] [PDF]